Preclinical Evaluation of a Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System in Choroidal Neovascularization.

Published on Nov 9, 2019in Molecular therapy. Methods & clinical development4.533
· DOI :10.1016/J.OMTM.2019.10.013
Maria Hernandez8
Estimated H-index: 8
(University of Navarra),
Sergio Recalde17
Estimated H-index: 17
(University of Navarra)
+ 16 AuthorsPatricia Fernandez-Robredo16
Estimated H-index: 16
(University of Navarra)
Sources
Abstract
Abstract Age-related macular degeneration (AMD) is a progressive retinal disorder, characterised by imbalanced pro- and anti-angiogenic signals. The aim of this study was to evaluate the effect of ex vivo cell-based gene therapy with stable expression of human pigment epithelium derived factor (PEDF) release using the non-viral Sleeping Beauty (SB100X) transposon system delivered by miniplasmids free of antibiotic resistance markers (pFAR4). Retinal pigment epithelial cells (RPEs) and iris pigment epithelial cells (IPEs) were co-transfected with pFAR4-ITRs CMV PEDF BGH and pFAR4-CMV-SB100X-SV40 plasmids. Laser-induced choroidal neovascularization (CNV) was performed in rats and transfected primary cells (tRPE and tIPE) were injected into the subretinal space. The leakage and CNV areas, vascular endothelial growth factor (VEGF), PEDF protein expression, metalloproteinase 2 and 9 (MMP-2/9) and microglial/macrophage markers were measured. Injection with tRPE/IPE cells significantly reduced the leakage area at 7 and 14 days and the CNV area at 7 days. There was a significant increase in PEDF and PEDF/VEGF ratio with tRPE cells and a reduction in the MMP-2 activity. Our data demonstrated that ex vivo non-viral gene therapy reduces CNV and could be an effective and safe therapeutic option for angiogenic retinal diseases.
📖 Papers frequently viewed together
89 Citations
References100
Newest
Widespread treatment of human diseases with gene therapies necessitates the development of gene transfer vectors that integrate genetic information effectively, safely and economically. Indeed, significant efforts have been devoted to engineer novel tools that (i) achieve high-level stable gene transfer at low toxicity to the host cell; (ii) induce low levels of genotoxicity and possess a `safe’ integration profile with a high proportion of integrations into safe genomic locations; and (iii) are...
22 CitationsSource
#1Amir H. Kashani (SC: University of Southern California)H-Index: 26
#2Jane LebkowskiH-Index: 2
Last. Mark S. Humayun (SC: University of Southern California)H-Index: 85
view all 16 authors...
Retinal pigment epithelium (RPE) dysfunction and loss are a hallmark of non-neovascular age-related macular degeneration (NNAMD). Without the RPE, a majority of overlying photoreceptors ultimately degenerate, leading to severe, progressive vision loss. Clinical and histological studies suggest that RPE replacement strategies may delay disease progression or restore vision. A prospective, interventional, U.S. Food and Drug Administration–cleared, phase 1/2a study is being conducted to assess the ...
131 CitationsSource
#1Marta Holstein (Paul Ehrlich Institute)H-Index: 1
Last. Zoltán Ivics (Paul Ehrlich Institute)H-Index: 34
view all 20 authors...
The Sleeping Beauty (SB) transposon system is a non-viral gene delivery platform that combines simplicity, inexpensive manufacture, and favorable safety features in the context of human applications. However, efficient correction of hematopoietic stem and progenitor cells (HSPCs) with non-viral vector systems, including SB, demands further refinement of gene delivery techniques. We set out to improve SB gene transfer into hard-to-transfect human CD34 + cells by vectorizing the SB system componen...
26 CitationsSource
#1Lyndon da CruzH-Index: 34
#2Kate Fynes (UCL: University College London)H-Index: 5
Last. Peter J. CoffeyH-Index: 50
view all 28 authors...
An engineered patch of retinal pigment epithelium generated from human embryonic stem cells is transplanted into the eyes of two patients.
232 CitationsSource
#1Laura Garcia-Garcia (University of Navarra)H-Index: 5
#2Sergio Recalde (University of Navarra)H-Index: 17
Last. Alfredo García-Layana (University of Navarra)H-Index: 25
view all 16 authors...
Pigment epithelium derived factor (PEDF) is a potent antiangiogenic, neurotrophic, and neuroprotective molecule that is the endogenous inhibitor of vascular endothelial growth factor (VEGF) in the retina. An ex vivo gene therapy approach based on transgenic overexpression of PEDF in the eye is assumed to rebalance the angiogenic-antiangiogenic milieu of the retina, resulting in growth regression of choroidal blood vessels, the hallmark of neovascular age-related macular degeneration. Here, we sh...
9 CitationsSource
#1Marie PastorH-Index: 2
#2Sandra Johnen (RWTH Aachen University)H-Index: 13
Last. Corinne MarieH-Index: 8
view all 12 authors...
The anti-angiogenic and neurogenic pigment epithelium-derived factor (PEDF) demonstrated a potency to control choroidal neovascularization in age-related macular degeneration (AMD) patients. The goal of the present study was the development of an efficient and safe technique to integrate, ex vivo, the PEDF gene into retinal pigment epithelial (RPE) cells for later transplantation to the subretinal space of AMD patients to allow continuous PEDF secretion in the vicinity of the affected macula. Be...
5 CitationsSource
#1Partow Kebriaei (University of Texas MD Anderson Cancer Center)H-Index: 64
#2Zsuzsanna Izsvák (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 60
Last. Zoltán Ivics (Paul Ehrlich Institute)H-Index: 34
view all 5 authors...
The widespread clinical implementation of gene therapy requires the ability to stably integrate genetic information through gene transfer vectors in a safe, effective, and economical manner. The latest generation of Sleeping Beauty (SB) transposon vectors fulfills these requirements, and may overcome limitations associated with viral gene transfer vectors and transient nonviral gene delivery approaches that are prevalent in ongoing clinical trials. The SB system enables high-level stable gene tr...
50 CitationsSource
#1William Hollingworth (UoB: University of Bristol)H-Index: 64
#2Timothy Jones (University Hospitals Bristol NHS Foundation Trust)H-Index: 33
Last. Tunde Peto ('QUB': Queen's University Belfast)H-Index: 49
view all 4 authors...
Objectives High-cost antivascular endothelial growth factor (anti-VEGF) medicines for eye disorders challenge ophthalmologists and policymakers to provide fair access for patients while minimising costs. We describe the growth in the use and costs of these medicines and measure inequalities in access. Design Longitudinal study using Hospital Episode Statistics (2005/2006 to 2014/2015) and hospital prescribing cost reports (2008/2009 to 2015/2016). We used Poisson regression to estimate standardi...
21 CitationsSource
#1Russ Hodge (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 4
#1HodgeRuss (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 1
Last. IvicsZoltán (Paul Ehrlich Institute)H-Index: 1
view all 4 authors...
Gene therapies will only become a widespread tool in the clinical treatment of human diseases with the advent of gene transfer vectors that integrate genetic information stably, safely, effectively, and economically. Two decades after the discovery of the Sleeping Beauty (SB) transposon, it has been transformed into a vector system that is fulfilling these requirements. SB may well overcome some of the limitations associated with viral gene transfer vectors and transient non-viral gene delivery ...
12 CitationsSource
#1Rupert R A Bourne (ARU: Anglia Ruskin University)H-Index: 3
#1Rupert R A Bourne (ARU: Anglia Ruskin University)H-Index: 3
Last. Yingfeng Zheng (Singapore National Eye Center)H-Index: 13
view all 106 authors...
Summary Background Global and regional prevalence estimates for blindness and vision impairment are important for the development of public health policies. We aimed to provide global estimates, trends, and projections of global blindness and vision impairment. Methods We did a systematic review and meta-analysis of population-based datasets relevant to global vision impairment and blindness that were published between 1980 and 2015. We fitted hierarchical models to estimate the prevalence (by a...
856 CitationsSource
Cited By5
Newest
Transposons are mobile genetic elements evolved to execute highly efficient integration of their genes into the genomes of their host cells. These natural DNA transfer vehicles have been harnessed as experimental tools for stably introducing a wide variety of foreign DNA sequences, including selectable marker genes, reporters, shRNA expression cassettes, mutagenic gene trap cassettes, and therapeutic gene constructs into the genomes of target cells in a regulated and highly efficient manner. Giv...
Source
#2Sergio RecaldeH-Index: 17
view all 16 authors...
The purpose of this study is evaluate the efficacy and safety of medicinal products containing the original Age-Related Eye Disease group (AREDS) formulation at doses approved in Europe (EU, control group; n = 59) with a product that adds DHA, lutein, zeaxanthin, resveratrol and hydroxytyrosol to the formula (intervention group; n = 50). This was a multicenter, randomized, observer-blinded trial conducted in patients aged 50 years or older diagnosed with unilateral exudative Age related Macular ...
2 CitationsSource
#1María L. Formica (CONICET: National Scientific and Technical Research Council)
#1María Lina Formica (National University of Cordoba)H-Index: 3
Last. Santiago Daniel Palma (National University of Cordoba)H-Index: 21
view all 3 authors...
Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti-VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off-label used in the clinical practice. The schedule dosage involves repeated intravitreal injections of anti-VEGF agents to achieve and maintain effective concentrations in retina and choroids, which are administrate...
Source
#1Alicia Arranz-Romera (Complutense University of Madrid)H-Index: 5
#2Maria Hernandez (University of Navarra)H-Index: 8
Last. Irene Bravo-Osuna (Complutense University of Madrid)H-Index: 20
view all 11 authors...
We assessed the sustained delivery effect of poly (lactic-co-glycolic) acid (PLGA)/vitamin E (VitE) microspheres (MSs) loaded with glial cell-derived neurotrophic factor (GDNF) alone (GDNF-MSs) or combined with brain-derived neurotrophic factor (BDNF; GDNF/BDNF-MSs) on migration of the human adult retinal pigment epithelial cell-line-19 (ARPE-19) cells, primate choroidal endothelial (RF/6A) cells, and the survival of isolated mouse retinal ganglion cells (RGCs). The morphology of the MSs, partic...
Source
#1Maximilian Amberger (Paul Ehrlich Institute)H-Index: 2
#2Zoltán Ivics (Paul Ehrlich Institute)H-Index: 57
The Sleeping Beauty transposon system is a nonviral DNA transfer tool capable of efficiently mediating transposition-based, stable integration of DNA sequences of choice into eukaryotic genomes. Continuous refinements of the system, including the emergence of hyperactive transposase mutants and novel approaches in vectorology, greatly improve upon transposition efficiency rivaling viral-vector-based methods for stable gene insertion. Current developments, such as reversible transgenesis and proo...
4 CitationsSource